News Tocagen’s brain tumour candidate gets PRIME designation An early-stage drug candidate for hard-to-treat brain tumours has been granted special ‘PRIME’ status by the European Medicines Agency.
News Tocagen aims for IPO to fund brain cancer trial Brain cancer specialist Tocagen is to become the latest biotech to test the waters with an IPO this year, after mixed success for recent market launches.
News Third Rock in $2bn drug-hunting pact with China's Funnel New Chinese biotech Funnel has signed a $2bn-plus partnership with Third Rock Ventures, focused on using its AI platform to discover novel biologics.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.
